Performance of lymphadenectomy for apparent early stage malignant ovarian germ cell tumors in the era of platinum-based chemotherapy.
Gynecol Oncol
; 157(3): 613-618, 2020 06.
Article
en En
| MEDLINE
| ID: mdl-32359845
ABSTRACT
OBJECTIVES:
To investigate the patterns of use and impact of lymphadenectomy (LND) on overall survival (OS) of patients with apparent early stage malignant ovarian germ cell tumors (MOGCTs).METHODS:
Patients with apparent stage I MOGCT diagnosed between 2004 and 2015 were drawn from the National Cancer Database. The performance of LND was assessed from the pathology report. OS was evaluated using Kaplan-Meier curves, and compared with the log-rank test. A multivariate Cox analysis was performed to control for confounders.RESULTS:
A total of 2774 patients were identified; 1426 (51.4%) underwent LND. The median number of lymph nodes (LN) removed was 9 (range 1-81); 48.3% of patients had at least 10 lymph nodes removed. The rate of regional lymph node metastasis was 10.3% (147 patients). There was no difference in OS, between patients who did (n = 1287) and did not (n = 1210) undergo LND, p = 0.81; 5-yr OS rates were 96.5% and 97.6% respectively. After controlling for patient age, insurance status, histology, presence of medical comorbidities, and receipt of chemotherapy, the performance of LND was not associated with better survival (HR 1.33, 95% CI 0.82, 2.14).CONCLUSIONS:
While LN metastasis is common in apparent early stage MOGCTs, the performance of LND was not associated with a survival benefit.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias Ováricas
/
Platino (Metal)
/
Neoplasias de Células Germinales y Embrionarias
/
Escisión del Ganglio Linfático
Límite:
Adolescent
/
Adult
/
Humans
/
Middle aged
Idioma:
En
Revista:
Gynecol Oncol
Año:
2020
Tipo del documento:
Article